uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

uniQure BV (QURE) PT Raised to $72 at B.Riley/FBRNovember 15, 2018 9:58 AM uniQure BV (QURE) PT Raised to $65 at Cantor FitzgeraldNovember 15, 2018 9:36 AM uniQure BV (QURE) PT Raised to 'Street High' $76 at Leerink PartnersNovember 15, 2018 8:56 AM uniQure (QURE) Climbs 40% After Reporting Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia BNovember 15, 2018 7:20 AM uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia BNovember 15, 2018 7:00 AM